Therapeutic Advances in Advanced Basal Cell Carcinoma
Basal cell carcinoma (BCC) is the most common type of cancer with an estimated 3.6 million cases diagnosed annually in the US alone. While most cases are treatable with low recurrence rates, 1-10% progress to an advanced stage which can behave aggressively, leading to local destruction and posing su...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-09, Vol.16 (17), p.3075 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 17 |
| container_start_page | 3075 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Alkassis, Samer Shatta, Maya Wong, Deborah J |
| description | Basal cell carcinoma (BCC) is the most common type of cancer with an estimated 3.6 million cases diagnosed annually in the US alone. While most cases are treatable with low recurrence rates, 1-10% progress to an advanced stage which can behave aggressively, leading to local destruction and posing substantial challenges in management. The pathogenesis often involves dysregulation of the patched/hedgehog protein family, a pivotal pathway targeted by recently approved therapies. Furthermore, the role of immunotherapy is evolving in this type of tumor as we learn more about tumor microenvironment dynamics. In recent years, there have been advancements in the therapeutic landscape of advanced BCC, offering patients new hope and options for managing this complex and potentially life-threatening condition. In this review, we aim to provide a comprehensive overview of this disease, including the risk factors, underlying pathogenesis, current treatment options of advanced disease, and the ongoing exploration and development of novel therapies. |
| doi_str_mv | 10.3390/cancers16173075 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3104539801</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3103792921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c250t-f835956a1fff9d9731c5c86f55c2aa86df66a68fbfcfecdd7d5175572eb412ae3</originalsourceid><addsrcrecordid>eNpdkM1LAzEQxYMottSevcmCFy9rk8wm2RxrqR9Q8FLPyzQfuGU_atIV_O_dpa1I5zDzDr95PB4ht4w-Amg6M9gYFyKTTAFV4oKMOVU8lVJnl__0iExj3NJ-AJiS6pqMQHPFNcCYiPWnC7hz3b40ydx-D5YxKZuTtskTRqyShav6hcGUTVvjDbnyWEU3Pd4J-Xherhev6er95W0xX6WGC7pPfQ5CC4nMe6-tVsCMMLn0QhiOmEvrpUSZ-4033hlrlRVMCaG422SMo4MJeTj47kL71bm4L-oymj4KNq7tYgGMZgJ0TlmP3p-h27YLTZ9uoEBprvlAzQ6UCW2MwfliF8oaw0_BaDGUWpyV2n_cHX27Te3sH3-qEH4BdnJx_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3103792921</pqid></control><display><type>article</type><title>Therapeutic Advances in Advanced Basal Cell Carcinoma</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Alkassis, Samer ; Shatta, Maya ; Wong, Deborah J</creator><creatorcontrib>Alkassis, Samer ; Shatta, Maya ; Wong, Deborah J</creatorcontrib><description>Basal cell carcinoma (BCC) is the most common type of cancer with an estimated 3.6 million cases diagnosed annually in the US alone. While most cases are treatable with low recurrence rates, 1-10% progress to an advanced stage which can behave aggressively, leading to local destruction and posing substantial challenges in management. The pathogenesis often involves dysregulation of the patched/hedgehog protein family, a pivotal pathway targeted by recently approved therapies. Furthermore, the role of immunotherapy is evolving in this type of tumor as we learn more about tumor microenvironment dynamics. In recent years, there have been advancements in the therapeutic landscape of advanced BCC, offering patients new hope and options for managing this complex and potentially life-threatening condition. In this review, we aim to provide a comprehensive overview of this disease, including the risk factors, underlying pathogenesis, current treatment options of advanced disease, and the ongoing exploration and development of novel therapies.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16173075</identifier><identifier>PMID: 39272933</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Arsenic ; Basal cell carcinoma ; Cancer therapies ; Cell cycle ; Disease management ; Disease resistance ; FDA approval ; Fibroblasts ; Hedgehog protein ; Immune checkpoint inhibitors ; Immune system ; Immunotherapy ; Lymphocytes ; Metastases ; Metastasis ; Mutagenesis ; Mutation ; Pathogenesis ; Patients ; Proteins ; Quality of life ; Radiation therapy ; Risk factors ; Skin cancer ; Surgery ; Tumor microenvironment ; Tumors ; Ultraviolet radiation</subject><ispartof>Cancers, 2024-09, Vol.16 (17), p.3075</ispartof><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c250t-f835956a1fff9d9731c5c86f55c2aa86df66a68fbfcfecdd7d5175572eb412ae3</cites><orcidid>0000-0002-0069-8854 ; 0000-0002-7811-7247</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39272933$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alkassis, Samer</creatorcontrib><creatorcontrib>Shatta, Maya</creatorcontrib><creatorcontrib>Wong, Deborah J</creatorcontrib><title>Therapeutic Advances in Advanced Basal Cell Carcinoma</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Basal cell carcinoma (BCC) is the most common type of cancer with an estimated 3.6 million cases diagnosed annually in the US alone. While most cases are treatable with low recurrence rates, 1-10% progress to an advanced stage which can behave aggressively, leading to local destruction and posing substantial challenges in management. The pathogenesis often involves dysregulation of the patched/hedgehog protein family, a pivotal pathway targeted by recently approved therapies. Furthermore, the role of immunotherapy is evolving in this type of tumor as we learn more about tumor microenvironment dynamics. In recent years, there have been advancements in the therapeutic landscape of advanced BCC, offering patients new hope and options for managing this complex and potentially life-threatening condition. In this review, we aim to provide a comprehensive overview of this disease, including the risk factors, underlying pathogenesis, current treatment options of advanced disease, and the ongoing exploration and development of novel therapies.</description><subject>Arsenic</subject><subject>Basal cell carcinoma</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Disease management</subject><subject>Disease resistance</subject><subject>FDA approval</subject><subject>Fibroblasts</subject><subject>Hedgehog protein</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Lymphocytes</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mutagenesis</subject><subject>Mutation</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Proteins</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Risk factors</subject><subject>Skin cancer</subject><subject>Surgery</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><subject>Ultraviolet radiation</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkM1LAzEQxYMottSevcmCFy9rk8wm2RxrqR9Q8FLPyzQfuGU_atIV_O_dpa1I5zDzDr95PB4ht4w-Amg6M9gYFyKTTAFV4oKMOVU8lVJnl__0iExj3NJ-AJiS6pqMQHPFNcCYiPWnC7hz3b40ydx-D5YxKZuTtskTRqyShav6hcGUTVvjDbnyWEU3Pd4J-Xherhev6er95W0xX6WGC7pPfQ5CC4nMe6-tVsCMMLn0QhiOmEvrpUSZ-4033hlrlRVMCaG422SMo4MJeTj47kL71bm4L-oymj4KNq7tYgGMZgJ0TlmP3p-h27YLTZ9uoEBprvlAzQ6UCW2MwfliF8oaw0_BaDGUWpyV2n_cHX27Te3sH3-qEH4BdnJx_Q</recordid><startdate>20240904</startdate><enddate>20240904</enddate><creator>Alkassis, Samer</creator><creator>Shatta, Maya</creator><creator>Wong, Deborah J</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0069-8854</orcidid><orcidid>https://orcid.org/0000-0002-7811-7247</orcidid></search><sort><creationdate>20240904</creationdate><title>Therapeutic Advances in Advanced Basal Cell Carcinoma</title><author>Alkassis, Samer ; Shatta, Maya ; Wong, Deborah J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c250t-f835956a1fff9d9731c5c86f55c2aa86df66a68fbfcfecdd7d5175572eb412ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Arsenic</topic><topic>Basal cell carcinoma</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Disease management</topic><topic>Disease resistance</topic><topic>FDA approval</topic><topic>Fibroblasts</topic><topic>Hedgehog protein</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Lymphocytes</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mutagenesis</topic><topic>Mutation</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Proteins</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Risk factors</topic><topic>Skin cancer</topic><topic>Surgery</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><topic>Ultraviolet radiation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alkassis, Samer</creatorcontrib><creatorcontrib>Shatta, Maya</creatorcontrib><creatorcontrib>Wong, Deborah J</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alkassis, Samer</au><au>Shatta, Maya</au><au>Wong, Deborah J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Therapeutic Advances in Advanced Basal Cell Carcinoma</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-09-04</date><risdate>2024</risdate><volume>16</volume><issue>17</issue><spage>3075</spage><pages>3075-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Basal cell carcinoma (BCC) is the most common type of cancer with an estimated 3.6 million cases diagnosed annually in the US alone. While most cases are treatable with low recurrence rates, 1-10% progress to an advanced stage which can behave aggressively, leading to local destruction and posing substantial challenges in management. The pathogenesis often involves dysregulation of the patched/hedgehog protein family, a pivotal pathway targeted by recently approved therapies. Furthermore, the role of immunotherapy is evolving in this type of tumor as we learn more about tumor microenvironment dynamics. In recent years, there have been advancements in the therapeutic landscape of advanced BCC, offering patients new hope and options for managing this complex and potentially life-threatening condition. In this review, we aim to provide a comprehensive overview of this disease, including the risk factors, underlying pathogenesis, current treatment options of advanced disease, and the ongoing exploration and development of novel therapies.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>39272933</pmid><doi>10.3390/cancers16173075</doi><orcidid>https://orcid.org/0000-0002-0069-8854</orcidid><orcidid>https://orcid.org/0000-0002-7811-7247</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-09, Vol.16 (17), p.3075 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3104539801 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Arsenic Basal cell carcinoma Cancer therapies Cell cycle Disease management Disease resistance FDA approval Fibroblasts Hedgehog protein Immune checkpoint inhibitors Immune system Immunotherapy Lymphocytes Metastases Metastasis Mutagenesis Mutation Pathogenesis Patients Proteins Quality of life Radiation therapy Risk factors Skin cancer Surgery Tumor microenvironment Tumors Ultraviolet radiation |
| title | Therapeutic Advances in Advanced Basal Cell Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Therapeutic%20Advances%20in%20Advanced%20Basal%20Cell%20Carcinoma&rft.jtitle=Cancers&rft.au=Alkassis,%20Samer&rft.date=2024-09-04&rft.volume=16&rft.issue=17&rft.spage=3075&rft.pages=3075-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16173075&rft_dat=%3Cproquest_cross%3E3103792921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3103792921&rft_id=info:pmid/39272933&rfr_iscdi=true |